Revance Therapeutics Inc (RVNC) Company Profile & Statistics

Revance Therapeutics Inc
RVNC
(Nasdaq - US)
Closed
3.72
-0.12 (-3.13%)
in:usd•As of: Nov 22, 2024 15:59 UTC -5
After Market:3.73+0.01 (+0.27%)
Open
3.80
High
3.89
Low
3.69

About Revance Therapeutics Inc

CEO

Mark J. Foley

Headquarters

1222 demonbreun street, suite 2000

nashville, tn 37203, united states

Auditor

PricewaterhouseCoopers LLP

Employees

597

Share Holders

155

Website

www.revance.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS? peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.

Revance Therapeutics Inc Statistics

Valuation Measures

Market Capitalization ²	390.23M
Enterprise Value	773.21M
Enterprise Value/EBITDA (ttm)	-2.71
Price to Earnings Ratio (ttm)	N/A
Price to Book (mrq)	N/A
Price to Sales (ttm)	1.58
Price to Cash (ytd)	N/A

Profitability

Gross Margin (ttm)	70.11%
Operating Margin (ttm)	-73.20%
Profit Margin (ttm)	-73.29%
Return on Equity (ttm)	N/A
Return on Invested Capital (ttm)	-107.42%
Return on Assets (ttm)	-37.22%

Income Statement

Revenue (ttm)	256.94M
Revenue Per Share (ttm)	2.45
Gross Profit (ttm)	179.32M
EBITDA (ttm)³	-285.71M
Net Income Avi to Common (ttm)	-184.44M
Diluted EPS (ttm)	-1.93

Share Statistics

Beta (5Y Monthly)	0.95
52-Week Change	-50.17%
S&P500 52-Week Change	31.18%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	104.90M
Dividend Yield	0.00%
Float ⁴	99.55M
% Held by Insiders	5.10%
% Held by Institutions	97.70%

Balance Sheet

Total Cash (mrq)	184.54M
Total Cash Per Share (mrq)	1.76
Total Debt (mrq)	442.03M
Total Debt/Equity (mrq)	-271.14%
Current Ratio (mrq)	4.12%
Quick Ratio (mrq)	3.05%
Book Value Per Share (mrq)	-1.55

Cash Flow

Operating Cash Flow Per Share (ytd)	-1.42
Free Cash Flow (ytd)	-150.40M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Revance Therapeutics Inc

Trade With A Regulated Broker